Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(1)
Other(1)

Detailed Status

Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

withdrawn150%
unknown150%

Recent Activity

0 active trials
Showing 2 of 2
withdrawnphase_1

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

NCT06608940
unknownphase_1

Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

NCT05970822

Clinical Trials (2)

Showing 2 of 2 trials
NCT06608940Phase 1

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Withdrawn
NCT05970822Phase 1

Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

Unknown

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2